Wall Street Analysts See Upside Potential of 3.9% in TEVA

Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.